Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake. A long streak doesn't necessarily make a dividend stock a good long-term buy. After all, those increases may only be modest, for the sake of keeping the streak going. And if a company increases its dividend by just one or two percentage points, that's not even going to offset inflation.What Eli Lilly (LLY -0.05%) is doing is far more impressive. The company has been increasing its di ...

China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024INDIANAPOLIS, Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's ...

Lilly just gave investors more reasons to cheer the company on.Pharmaceutical giant Eli Lilly (LLY -0.10%) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster diabetes and obesity care medications, Mounjaro and Zepbound.The excitement surrounding the weight loss market has fueled a stock-buying frenzy, propelling Lilly to a market capitalization of roughly $720 billion -- making it the most valuable pharmaceu ...

The international pharmaceutical giant Eli Lilly (NYSE: LLY ) has shown tremendous growth in the last few years. The growth happened thanks to its robust product portfolio, strategic acquisitions, and innovation-led initiatives. The company, which specializes in solving the world's most severe healthcare issues, isComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but ...

This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030INDIANAPOLIS and CAIRO, Dec. 17, 2024 /PRNewswire/ -- The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and ...

Eli Lilly (LLY) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its IL-23p19 antibody Omvoh (mirikizumab) for expanded use in Crohn’s disease (CD).The CHMP has recommended Omvoh to treat adults with moderately to severely active CD, who have had an inadequate response with, lost response to, or are intolerant to conventional or biologic therapies. A final decision from the European Commission is now expected in the next one or two months.This positive r ...

SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Eli Lilly and Company (NYSE: LLY) today jointly announced a Distribution and Promotion Agreement in Mainland China regarding Lilly's non-covalent (reversible) Bruton's t ...

Core Viewpoint - Eli Lilly is experiencing significant growth driven by its diabetes drug Mounjaro and weight loss drug Zepbound, but there are concerns about sustaining this growth and the company's high valuation [2][8][10]. Group 1: Growth Drivers - Eli Lilly's operating income has increased by 90.7% over the last three years, reaching $15.1 billion, largely due to the success of Mounjaro and Zepbound [2]. - The company is investing heavily in manufacturing, with a recent $3 billion expansion in Wisconsin, bringing total investment in the site to $4 billion, indicating expectations for increased demand [3][4]. - Clinical trials suggest Zepbound is more effective for weight loss than its competitor Wegovy, with patients losing 47% more weight after 72 weeks, which could enhance market share [6]. Group 2: Cautionary Factors - There are signs that the rapid growth may be slowing, as drug wholesalers purchased fewer doses of Mounjaro and Zepbound in Q3 compared to previous quarters [8]. - Management indicated that wholesalers had previously stocked up on GLP-1 drugs, leading to a temporary inventory surplus, which may affect future sales growth [9]. - Eli Lilly's trailing P/E ratio is 86, indicating a high valuation that may lead to volatility if earnings do not meet investor expectations [10][11].

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these co ...

With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.There are a pair of businesses that are particularly appealing on the basis of their proven or potential ability to compete in that market. Both of these companies have outperformed the market for at least the last 12 months, and there's ample reason to believe that the outperformance could continu ...